Literature DB >> 17258175

Identification of Dok-4b, a Dok-4 splice variant with enhanced inhibitory properties.

Cindy Baldwin1, Arda Bedirian, Hongping Li, Tomoko Takano, Serge Lemay.   

Abstract

Dok adapter proteins have been primarily implicated in negative regulation of tyrosine kinase signaling, but Dok-4 has been reported to exert both inhibitory and stimulatory effects. We have identified a splice variant of Dok-4, Dok-4b, which contains a 39 aa insert within the its C-terminal region. The approximately 45kDa Dok-4b protein was detected in several human epithelial cell lines. Based on genomic sequences, Dok-4b was also predicted to exist in primates and possibly bovines, but not in rodents or other species. Compared to Dok-4, Dok-4b inhibited the tyrosine kinase-induced activation of both Erk and Elk-1 more strongly. Truncation of the C-terminal region of Dok-4 (Dok-4 DeltaCT) also enhanced the inhibitory activity of Dok-4, whereas expression of the isolated C-terminal domain enhanced Elk-1 activation, suggesting that the N-terminus and C-terminus of Dok-4 possess opposing inhibitory and stimulatory properties, respectively, the balance of which is altered by alternative splicing of Dok-4 to Dok-b.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17258175     DOI: 10.1016/j.bbrc.2007.01.054

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Dok-4 is a novel negative regulator of T cell activation.

Authors:  Audrey Gérard; Marguerite Ghiotto; Camille Fos; Geoffrey Guittard; Daniel Compagno; Anne Galy; Serge Lemay; Daniel Olive; Jacques A Nunès
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

2.  Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancer.

Authors:  Teresa Friedrich; Michaela Söhn; Tobias Gutting; Klaus-Peter Janssen; Hans-Michael Behrens; Christoph Röcken; Matthias P A Ebert; Elke Burgermeister
Journal:  EBioMedicine       Date:  2016-05-05       Impact factor: 8.143

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.